Literature DB >> 8657154

Analysis of wild-type and mutant p21WAF-1 gene activities.

J Lin1, C Reichner, X Wu, A J Levine.   

Abstract

The p21WAF-1 gene is positively regulated by the wild-type p53 protein. p21WAF-1 has been shown to interact with several cyclin-dependent kinase complexes and block the activity of G1 cyclin-dependent kinases (cdks). Mutational analysis with the p21WAF-1 gene localized a site, at amino acid residues 21 and 24 in the amino terminus of the protein, for p21WAF-1 binding to cyclins D and E. This region of the protein is conserved (residues 21 to 26) in other p21WAF-1 family members, p27kip-1 and p57kip-2. The same p21WAF-121,24 mutant also fails to bind to cyclin D1-cdk 4 or cyclin E-cdk 2 complexes in vitro, suggesting that amino acid residues 21 and 24 are important for p21WAF-1-cdk-cyclin trimeric complex interactions. The p21WAF-1 wild-type protein will suppress tumor cell growth in culture while p21WAF-1 mutant proteins with defects in residues 21 and 24 fail to suppress tumor cell growth. The overexpression of cyclin D or E in these cells will partially overcome the growth suppression of wild-type p21WAF-1 protein in cells. These results provide evidence that p21WAF-1 acts through cyclin D1-cdk4 and cyclin E-cdk2 complexes in vivo to induce the growth suppression. The p21WAF-1 binding sites for cyclins (residues 21 to 26), cdk2 (residues 49 to 71), and proliferating-cell nuclear antigen (residues 124 to 164) have all been mapped to discrete sites on the protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8657154      PMCID: PMC231165          DOI: 10.1128/MCB.16.4.1786

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  48 in total

1.  p53 functions as a cell cycle control protein in osteosarcomas.

Authors:  L Diller; J Kassel; C E Nelson; M A Gryka; G Litwak; M Gebhardt; B Bressac; M Ozturk; S J Baker; B Vogelstein
Journal:  Mol Cell Biol       Date:  1990-11       Impact factor: 4.272

2.  Cellular localization and cell cycle regulation by a temperature-sensitive p53 protein.

Authors:  J Martinez; I Georgoff; J Martinez; A J Levine
Journal:  Genes Dev       Date:  1991-02       Impact factor: 11.361

3.  Transcriptional activation by wild-type but not transforming mutants of the p53 anti-oncogene.

Authors:  L Raycroft; H Y Wu; G Lozano
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

4.  Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53.

Authors:  D Michalovitz; O Halevy; M Oren
Journal:  Cell       Date:  1990-08-24       Impact factor: 41.582

Review 5.  Cell cycle control in eukaryotes: molecular mechanisms of cdc2 activation.

Authors:  G Draetta
Journal:  Trends Biochem Sci       Date:  1990-10       Impact factor: 13.807

Review 6.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

7.  Presence of a potent transcription activating sequence in the p53 protein.

Authors:  S Fields; S K Jang
Journal:  Science       Date:  1990-08-31       Impact factor: 47.728

8.  Suppression of human colorectal carcinoma cell growth by wild-type p53.

Authors:  S J Baker; S Markowitz; E R Fearon; J K Willson; B Vogelstein
Journal:  Science       Date:  1990-08-24       Impact factor: 47.728

9.  p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features.

Authors:  T Mitsudomi; S M Steinberg; M M Nau; D Carbone; D D'Amico; S Bodner; H K Oie; R I Linnoila; J L Mulshine; J D Minna
Journal:  Oncogene       Date:  1992-01       Impact factor: 9.867

10.  The tumor suppression function of p21Waf is contained in its N-terminal half ('half-WAF').

Authors:  R Zakut; D Givol
Journal:  Oncogene       Date:  1995-07-20       Impact factor: 9.867

View more
  37 in total

1.  p21CIP1 and Cdc25A: competition between an inhibitor and an activator of cyclin-dependent kinases.

Authors:  P Saha; Q Eichbaum; E D Silberman; B J Mayer; A Dutta
Journal:  Mol Cell Biol       Date:  1997-08       Impact factor: 4.272

2.  p130 and p107 use a conserved domain to inhibit cellular cyclin-dependent kinase activity.

Authors:  M S Woo; I Sánchez; B D Dynlacht
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

3.  Specific regulation of E2F family members by cyclin-dependent kinases.

Authors:  B D Dynlacht; K Moberg; J A Lees; E Harlow; L Zhu
Journal:  Mol Cell Biol       Date:  1997-07       Impact factor: 4.272

4.  Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors.

Authors:  P D Adams; W R Sellers; S K Sharma; A D Wu; C M Nalin; W G Kaelin
Journal:  Mol Cell Biol       Date:  1996-12       Impact factor: 4.272

5.  Dual cyclin-binding domains are required for p107 to function as a kinase inhibitor.

Authors:  E Castaño; Y Kleyner; B D Dynlacht
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

6.  Human and yeast cdk-activating kinases (CAKs) display distinct substrate specificities.

Authors:  P Kaldis; A A Russo; H S Chou; N P Pavletich; M J Solomon
Journal:  Mol Biol Cell       Date:  1998-09       Impact factor: 4.138

7.  Substrate recruitment to cyclin-dependent kinase 2 by a multipurpose docking site on cyclin A.

Authors:  B A Schulman; D L Lindstrom; E Harlow
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

8.  Transcriptional repression of Bmp2 by p21(Waf1/Cip1) links quiescence to neural stem cell maintenance.

Authors:  Eva Porlan; José Manuel Morante-Redolat; María Ángeles Marqués-Torrejón; Celia Andreu-Agulló; Carmen Carneiro; Esther Gómez-Ibarlucea; Atenea Soto; Anxo Vidal; Sacri R Ferrón; Isabel Fariñas
Journal:  Nat Neurosci       Date:  2013-10-06       Impact factor: 24.884

9.  Human papillomavirus 18 E1^E4 protein interacts with cyclin A/CDK 2 through an RXL motif.

Authors:  Qingming Ding; Lili Li; Peter Whyte
Journal:  Mol Cell Biochem       Date:  2012-10-13       Impact factor: 3.396

Review 10.  Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.

Authors:  Zbigniew Darzynkiewicz; Frank Traganos; Donald Wlodkowic
Journal:  Eur J Pharmacol       Date:  2009-10-18       Impact factor: 4.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.